Expression, regulation and function of MicroRNAs in multiple sclerosis

International Journal of Medical Sciences

Volumn 11, Issue 8, 2014, Pages 810-818

  Ma, Xinting ^a   Zhou, Juhua ^a   Zhong, Yin ^b   Jiang, Linlin ^a   Mu, Ping ^a   Li, Yanmin ^a   Singh, Narendra ^b   Nagarkatti, Mitzi ^b   Nagarkatti, Prakash ^b  

^a LUDONG UNIVERSITY   (China)

^b UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarker; Gene expression; Gene regulation; miRNA; Multiple sclerosis; Therapeutic target

Indexed keywords

BETA INTERFERON; GLATIRAMER; MICRORNA; MICRORNA 142 3P; MICRORNA 146A; MICRORNA 146B; MICRORNA 155; MICRORNA 15A; MICRORNA 15B; MICRORNA 181C; MICRORNA 19A; MICRORNA 21; MICRORNA 210; MICRORNA 22; MICRORNA 223; MICRORNA 326; MICRORNA 328; UNCLASSIFIED DRUG;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DISEASE MARKER; DOWN REGULATION; DRUG TARGETING; GENE EXPRESSION; GENE SILENCING; HUMAN; MULTIPLE SCLEROSIS; NONHUMAN; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; REVIEW; UPREGULATION; WHITE MATTER; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; MOUSE; PATHOLOGY; REGULATORY T LYMPHOCYTE;

ANIMALS; GENE EXPRESSION REGULATION; GENE SILENCING; HUMANS; MICE; MICRORNAS; MOLECULAR TARGETED THERAPY; MULTIPLE SCLEROSIS; T-LYMPHOCYTES, REGULATORY;

EID: 84901844552     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.8647     Document Type: Review

References (58)

1. Compston A, Coles A. Multiple sclerosis. Lancet. 2002; 359: 1221-31.
2. Milo R, Kahana E. Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun Rev. 2010; 9: A387-94.
3. Tarassishin L, Loudig O, Bauman A et al. Interferon regulatory factor 3 inhibits astrocyte inflammatory gene expression through suppression of the proinflammatory miR-155 and miR-155. Glia. 2011; 59: 1911-22.
4. Smith KM, Guerau-de-Arellano M, Costinean S et al. miR-29ab1 deficiency identifies a negative feedback loop controlling Th1 bias that is dysregulated in multiple sclerosis. J Immunol. 2012; 189: 1567-76.
5. Keller A, Leidinger P, Steinmeyer F et al. Comprehensive analysis of microRNA profiles in multiple sclerosis including next-generation sequencing. Mult Scler. 2014; 20: 295-303.
6. Cox MB, Cairns MJ, Gandhi KS et al. MicroRNAs miR-17 and miR-20a inhibit T cell activation genes and are under-expressed in MS whole blood. PloS One. 2010; 5: e12132.
7. Gandhi R, Healy B, Gholipour T et al. Circulating microRNAs as biomarkers for disease staging in multiple sclerosis. Ann Neurol. 2013; 73: 729-40.
8. Siegel SR, Mackenzie J, Chaplin G et al. Circulating microRNAs involved in multiple sclerosis. Mol Biol Rep. 2012; 39: 6219-25.
9. Zhang J, Cheng Y, Cui W et al. MicroRNA-155 modulates Th1 and Th17 cell differentiation and is associated with multiple sclerosis and experimental autoimmune encephalomyelitis. J Neuroimmunol. 2013; 266: 56-63.
10. Fenoglio C, Ridolfi E, Cantoni C et al. Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis. Mult Scler. 2013; 19: 1938-42.
11. Keller A, Leidinger P, Lange J et al. Multiple sclerosis: microRNA expression profiles accurately differentiate patients with relapsing-remitting disease from healthy controls. PloS One. 2009; 4: e7440.
12. Sondergaard HB, Hesse D, Krakauer M et al. Differential microRNA expression in blood in multiple sclerosis. Mult Scler. 2013; 19: 1849-57.
13. Waschbisch A, Atiya M, Linker RA et al. Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis. PloS One. 2011; 6: e24604.
14. Du C, Liu C, Kang J et al. MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis. Nat Immunol. 2009; 10: 1252-9.
15. Fenoglio C, Cantoni C, De Riz M et al. Expression and genetic analysis of miRNAs involved in CD4+ cell activation in patients with multiple sclerosis. Neurosci Lett. 2011; 504: 9-12.
16. Paraboschi EM, Solda G, Gemmati D et al. Genetic association and altered gene expression of mir-155 in multiple sclerosis patients. Int J Mol Sci. 2011; 12: 8695-712.
17. Martinelli-Boneschi F, Fenoglio C, Brambilla P et al. MicroRNA and mRNA expression profile screening in multiple sclerosis patients to unravel novel pathogenic steps and identify potential biomarkers. Neurosci Lett. 2012; 508: 4-8.
18. Yang D, Wang WZ, Zhang XM et al. MicroRNA Expression Aberration in Chinese Patients with Relapsing Remitting Multiple Sclerosis. J Mol Neurosci. 2014; 52: 131-7.
19. Jernas M, Malmestrom C, Axelsson M et al. MicroRNA regulate immune pathways in T-cells in multiple sclerosis (MS). BMC Immunol. 2013; 14: 32.
20. Lorenzi JC, Brum DG, Zanette DL et al. miR-15a and 16-1 are downregulated in CD4+ T cells of multiple sclerosis relapsing patients. Int J Neurosci. 2012; 122: 466-71.
21. Guerau-de-Arellano M, Smith KM, Godlewski J et al. Micro-RNA dysregulation in multiple sclerosis favours pro-inflammatory T-cell-mediated autoimmunity. Brain. 2011; 134: 3578-89.
22. Lindberg RL, Hoffmann F, Mehling M et al. Altered expression of miR-17-5p in CD4+ lymphocytes of relapsing-remitting multiple sclerosis patients. Eur J Immunol. 2010; 40: 888-98.
23. De Santis G, Ferracin M, Biondani A et al. Altered miRNA expression in T regulatory cells in course of multiple sclerosis. J Neuroimmunol. 2010; 226: 165-71.
24. Sievers C, Meira M, Hoffmann F et al. Altered microRNA expression in B lymphocytes in multiple sclerosis: towards a better understanding of treatment effects. Clin Immunol. 2012; 144: 70-9.
25. Moore CS, Rao VT, Durafourt BA et al. miR-155 as a multiple sclerosis-relevant regulator of myeloid cell polarization. Ann Neurol. 2013; 74: 709-20.
26. Thamilarasan M, Koczan D, Hecker M et al. MicroRNAs in multiple sclerosis and experimental autoimmune encephalomyelitis. Autoimmun Rev. 2012; 11: 174-9.
27. Junker A. Pathophysiology of translational regulation by microRNAs in multiple sclerosis. FEBS Lett. 2011; 585: 3738-46.
28. Junker A, Krumbholz M, Eisele S et al. MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47. Brain. 2009; 132: 3342-52.
29. Noorbakhsh F, Ellestad KK, Maingat F et al. Impaired neurosteroid synthesis in multiple sclerosis. Brain. 2011; 134: 2703-21.
30. Shapshak P. Molecule of the month: miRNA and Multiple Sclerosis. Bioinformation. 2013; 9: 847-8.
31. Dutta R, Chomyk AM, Chang A et al. Hippocampal demyelination and memory dysfunction are associated with increased levels of the neuronal microRNA miR-124 and reduced AMPA receptors. Ann Neurol. 2013; 73: 637-45.
32. Haghikia A, Hellwig K, Baraniskin A et al. Regulated microRNAs in the CSF of patients with multiple sclerosis: a case-control study. Neurology. 2012; 79: 2166-70.
33. Lescher J, Paap F, Schultz V et al. MicroRNA regulation in experimental autoimmune encephalomyelitis in mice and marmosets resembles regulation in human multiple sclerosis lesions. J Neuroimmunol. 2012; 246: 27-33.
34. Guan H, Fan D, Mrelashvili D et al. MicroRNA let-7e is associated with the pathogenesis of experimental autoimmune encephalomyelitis. Eur JImmunol. 2013; 43: 104-14
35. Zhu S, Pan W, Song X et al. The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-alpha. Nat Med. 2012; 18: 1077-86
36. Kremenchutzky M, Morrow S, Rush C. The safety and efficacy of IFN-beta products for the treatment of multiple sclerosis. Expert Opin Drug Saf. 2007; 6: 279-88
37. Hecker M, Thamilarasan M, Koczan D et al. MicroRNA expression changes during interferon-beta treatment in the peripheral blood of multiple sclerosis patients. Int J Mol Sci. 2013; 14: 16087-110
38. Pollinger B. IL-17 producing T cells in mouse models of multiple sclerosis and rheumatoid arthritis. J Mol Med. 2012; 90: 613-24
39. Messina S, Patti F. The pharmacokinetics of glatiramer acetate for multiple sclerosis treatment. Expert OpinDrug Metab Toxicol. 2013; 9: 1349-59
40. Johnson KP, Due DL. Benefits of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis. Expert RevPharmacoecon Outcomes Res. 2009; 9: 205-14
41. Brown BA. Natalizumab in the treatment of multiple sclerosis. Ther Clin Risk Manag. 2009; 5: 585-94
42. Hanieh H, Alzahrani A. MicroRNA-132 suppresses autoimmune encephalomyelitis by inducing cholinergic anti-inflammation: a new Ahr-based exploration. Eur J Immunol. 2013; 43: 2771-82
43. Otaegui D, Baranzini SE, Armananzas R et al. Differential micro RNA expression in PBMC from multiple sclerosis patients. PloS One. 2009; 4: e6309
44. Nakahama T, Hanieh H, Nguyen NT et al. Aryl hydrocarbon receptor-mediated induction of the microRNA-132/212 cluster promotes interleukin-17-producing T-helper cell differentiation. Proc Natl Acad Sci U S A. 2013; 110: 11964-9
45. Reijerkerk A, Lopez-Ramirez MA, van Het Hof B et al. MicroRNAs regulate human brain endothelial cell-barrier function in inflammation: implications for multiple sclerosis. J Neurosci. 2013; 33: 6857-63
46. Angerstein C, Hecker M, Paap BK et al. Integration of MicroRNA databases to study MicroRNAs associated with multiple sclerosis. Mol Neurobiol. 2012; 45: 520-35
47. Ando Y, Yang GX, Kenny TP et al. Overexpression of microRNA-21 is associated with elevated pro-inflammatory cytokines in dominant-negative TGF-beta receptor type II mouse. J Autoimmun. 2013; 41: 111-9
48. Ding S, Liang Y, Zhao M et al. Decreased microRNA-142-3p/5p expression causes CD4+ T cell activation and B cell hyperstimulation in systemic lupus erythematosus. Arthritis and rheum. 2012; 64: 2953-63
49. Tobon KE, Chang D, Kuzhikandathil EV. MicroRNA 142-3p mediates post-transcriptional regulation of D1 dopamine receptor expression. PloS One. 2012; 7: e49288
50. Xia P, Fang X, Zhang ZH et al. Dysregulation of miRNA146a versus IRAK1 induces IL-17 persistence in the psoriatic skin lesions. Immunol Lett. 2012; 148: 151-62
51. Iyer A, Zurolo E, Prabowo A et al. MicroRNA-146a: a key regulator of astrocyte-mediated inflammatory response. PloS One.2012; 7: e44789
52. Nata T, Fujiya M, Ueno N et al. MicroRNA-146b improves intestinal injury in mouse colitis by activating nuclear factor-kappaB and improving epithelial barrier function. J Gene Med.2013; 15: 249-60
53. Curtale G, Mirolo M, Renzi TA et al. Negative regulation of Toll-like receptor 4 signaling by IL-10-dependent microRNA-146b. Proc Natl Acad Sci U S A. 2013; 110: 11499-504
54. Murugaiyan G, Beynon V, Mittal A et al. Silencing microRNA-155 ameliorates experimental autoimmune encephalomyelitis. J Immunol. 2011; 187: 2213-21
55. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993; 75: 843-54
56. Arora S, Rana R, Chhabra A et al. miRNA-transcription factor interactions: a combinatorial regulation of gene expression. Mol Genet Genomics. 2013; 288: 77-87
57. Singh RP, Massachi I, Manickavel S et al. The role of miRNA in inflammation and autoimmunity. Autoimmun Rev. 2013; 12: 1160-5
58. Bronevetsky Y, Ansel KM. Regulation of miRNA biogenesis and turnover in the immune system. Immunol Rev. 2013; 253: 304-16.